Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BSI-04702
- Development stage
- Phase 2
- Lead developer
- OBI Pharma
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
BSI-04702 is a humanized monoclonal antibody targeting **Trop-2** (tumor-associated calcium signal transducer 2/TACSTD2), with distinct properties compared to other anti-Trop-2 antibodies. It was developed using Biosion's proprietary SynTracer HT-endocytosis platform, designed to identify antibodies ideally suited for antibody-drug conjugate (ADC) development due to their high internalization rates. BSI-04702 is further being developed as an **ADC** with a topoisomerase I payload, primarily for use against a range of solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and gastric cancer. Biosion originally developed the antibody and subsequently out-licensed worldwide (excluding China) rights to OBI Pharma for clinical development and commercialization as an ADC and other derivative products[1][2][3][4][5][10][11].
- Other names
- OBI-992 TROP2 ADCOBI992 TROP2 ADCOBI 992 TROP2 ADC
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on BSI-04702.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BSI-04702.